37 related articles for article (PubMed ID: 8621231)
1. Determinants of drug response in a cisplatin-resistant human lung cancer cell line.
Fujiwara Y; Sugimoto Y; Kasahara K; Bungo M; Yamakido M; Tew KD; Saijo N
Jpn J Cancer Res; 1990 May; 81(5):527-35. PubMed ID: 2116401
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism.
Maeda S; Sugiura T; Saikawa Y; Kubota T; Otani Y; Kumai K; Kitajima M
Cancer Sci; 2004 Aug; 95(8):679-84. PubMed ID: 15298732
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells.
Arioka H; Nishio K; Ishida T; Fukumoto H; Fukuoka K; Nomoto T; Kurokawa H; Yokote H; Abe S; Saijo N
Jpn J Cancer Res; 1999 Jan; 90(1):108-15. PubMed ID: 10076573
[TBL] [Abstract][Full Text] [Related]
4. Association of ABCC2 and CDDP-Resistance in Two Sublines Resistant to CDDP Derived from a Human Nasopharyngeal Carcinoma Cell Line.
Xie SM; Fang WY; Liu TF; Yao KT; Zhong XY
J Oncol; 2010; 2010():915046. PubMed ID: 20628484
[TBL] [Abstract][Full Text] [Related]
5. Ligustrazine-Derived Chalcones-Modified Platinum(IV) Complexes Intervene in Cisplatin Resistance in Pancreatic Cancer through Ferroptosis and Apoptosis.
Wang M; Cao G; Zhou J; Cai J; Ma X; Liu Z; Huang X; Wang H
J Med Chem; 2023 Oct; 66(19):13587-13606. PubMed ID: 37766483
[TBL] [Abstract][Full Text] [Related]
6. Cancer cell membrane-camouflaged CuPt nanoalloy boosts chemotherapy of cisplatin prodrug to enhance anticancer effect and reverse cisplatin resistance of tumor.
Gan Y; Xie W; Wang M; Wang P; Li Q; Cheng J; Yan M; Xia J; Wu Z; Zhang G
Mater Today Bio; 2024 Feb; 24():100941. PubMed ID: 38269055
[TBL] [Abstract][Full Text] [Related]
7. Long-term complete response in supraclavicular lymph node metastases of esophageal cancer using systemic chemotherapy-a case report.
Zhang S; Shi W
Int J Clin Exp Pathol; 2019; 12(9):3679-3684. PubMed ID: 31934220
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of HIPK2 increases resistance of bladder cancer cell to cisplatin by regulating Wip1.
Lin J; Zhang Q; Lu Y; Xue W; Xu Y; Zhu Y; Hu X
PLoS One; 2014; 9(5):e98418. PubMed ID: 24846322
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling.
Wei Y; Shen N; Wang Z; Yang G; Yi B; Yang N; Qiu Y; Lu J
Mol Cell Biochem; 2013 Sep; 381(1-2):139-44. PubMed ID: 23756716
[TBL] [Abstract][Full Text] [Related]
10. Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site.
Kusaba H; Shibata Y; Arita S; Ariyama H; Baba E; Mitsugi K; Harada M; Nakano S
Med Oncol; 2007; 24(2):259-64. PubMed ID: 17848753
[TBL] [Abstract][Full Text] [Related]
11. Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.
Shibata Y; Baba E; Ariyama H; Miki R; Ogami N; Arita S; Qin B; Kusaba H; Mitsugi K; Noshiro H; Yao T; Nakano S
World J Gastroenterol; 2007 Jul; 13(26):3634-7. PubMed ID: 17659717
[TBL] [Abstract][Full Text] [Related]
12. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Tatsumoto T; Kuroki-Migita M; Mitsugi K; Nakamura M; Niho Y
Cancer Res; 1992 Dec; 52(23):6501-6. PubMed ID: 1423296
[TBL] [Abstract][Full Text] [Related]
13. Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
Zhan M; Liu X
Chin Med J (Engl); 1999 Apr; 112(4):336-9. PubMed ID: 11593534
[TBL] [Abstract][Full Text] [Related]
14. Intracellular calcium changes and chemosensitivities of human epidermoid carcinoma cell lines after exposure to cisplatin.
Tachikawa T; Kumazawa H; Hori Y; Harada N; Sai S; Yamashita T; Yodosawa S; Kawamoto K
Ann Otol Rhinol Laryngol; 1998 Jul; 107(7):611-8. PubMed ID: 9682858
[TBL] [Abstract][Full Text] [Related]
15. Resistance to cisplatin and analogues: mechanisms and potential clinical implications.
de Graeff A; Slebos RJ; Rodenhuis S
Cancer Chemother Pharmacol; 1988; 22(4):325-32. PubMed ID: 3048763
[TBL] [Abstract][Full Text] [Related]
16. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Masumoto N; Fujishima H; Niho Y
Int J Cancer; 1996 Feb; 65(4):479-84. PubMed ID: 8621231
[TBL] [Abstract][Full Text] [Related]
17. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
Fujishima H; Nakano S; Masumoto N; Esaki T; Tatsumoto T; Kondo T; Niho Y
Oncol Res; 1997; 9(4):167-72. PubMed ID: 9268987
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
